JFIF(Photoshop 3.08BIM @Dana-Farber Study Backs FDA Approval of Pembrolizumab-Belzutifan720260612PSCIENMAGUAuthorzDana-Farber Study Backs FDA Approval of Pembrolizumab-Belzutifan Combo for High-Risk Clear Cell Kidney Cancer Post-Surgery Science@https://scienmag.com/dana-farber-study-backs-fda-approval-of-pem© 2026 Sciencehttps://scienmag.com/In a landmark advancement for renal cell carcinoma (RCC) treatment, the U.S. Food and Drug Administration (FDA) has granted approval for a novel adjuvant therapy combining pembrolizumab, a well-known immune checkpoint inhibitor, with belzutifan, a pioneering hypoxia-inducible factor 2-alpha (HIF-2α) inhibitor. This therapeutic regimen is indicated for adult patients diagnosed with clear cell renal cell […]ScienceCanCancerCancer4adjuvant therapy for clear cell renal cell carcinoma3Dana-Farber Cancer Institute kidney cancer research1FDA approval pembrolizumab belzutifan combination-HIF-2α inhibitor belzutifan in kidney cancer*high-risk ccRCC post-nephrectomy treatment3intermediate-high risk renal cell carcinoma therapy0pembrolizumab belzutifan survival outcomes ccRCC-pembrolizumab immune checkpoint inhibitor RCC(phase 3 LITESPARK-022 clinical trial RCCC    !'"#%%%),($+!$%$C   $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$"B!1AQaq"2#BR%5bcr$34DstS9!1AQq3a"24#5bRr$% ?L:"ΛesU-;aPOYP@*Yh'N"%Io P4i${>-^!{W֚SeaTrRMDقwI4fm>㫁.xV󟛴YNl6ݤ}ŲSS6R{JFvVPbTifRj?qcDsKmIE_J]%̈ՀpÿeU5;ڌC0CHBX :<:ZmuWLT0\[#5jm#q<+oi ]'BOa=NR{mED$יm’ŰRD!۵UbmOJ컌̶-Ki'#d蚉n Z Ttڹ hqH׋i@L⬽\gFvjdIylIG!FZsɾWUTl=Gʊt/eRꉁ>8\4/jNݿ[BXZ.Is+wuVAZ$qW$[dn$Ilp #{s;F; 2dye5kQ 8QkVz!+n:y ƃwbi tQu溻r8Vڋn8ހZY\ ˋxF4;[ 0u.?* Nk*< P^I4ub,QkӼ{GʼIc.69lԮ.cVm}]^d44ZF:;}iނ8s-36[bwFW֔CX䃃b/=hSz73Q%̅h␆N:f=.)-(@VjշuL º <Ci B }k/]d q_}W9[jߨ}AJU*T?㾴niBv` Ib$YշVKRrVp*qHk8"fwO-E,2dЧOE%(4-;%Pm CJ{jC찢3Yڙtm>LN2=K Vm7w7ցn֠S1#9O;|5sJT꧖٫Ik)a<-'pY6ȏΓa xR8;זYˋ% of|!E$Ru/I^e /Xi<<7E#oօqS1N.Q*m#>{rR~;qqډk${0]۾q05wiU2^g榕}{`>& Ij8Dϟeմa&W -P20jQJ{UOSDˉmXZ1nfbGE?]Z`1dyvrKo;kT2\l"IVk|oOrֵp)!GgƉ'@#_rT0:g8#|k&:ZZJH$o,\g)NGʐVKefm8k?J!v!mL>7J܁*1"_e,4SIvc;x$35PMb;۞%PiS "K#8~@WM3`yˍk pcD%kK/ gSNg>(0CMGCE':)/) Vp{|?4N*4';f3)mւ9q$}+z;'b>/uU z>5pG|я}]S)iz-ng/)^9 $h zB ,yԬu"IӎuWJ~6c/ԟLem܋uwChIL7jR)?QYO ? P"Ǔ%\qW&'zarxA')Wņ>a+@QmhqRI R7y. kpqmF* i<߷>ۯQ$&dVe[Q p@zAXR vջC6[>IՆ˻%lud}wwK?4PiqnRR7`u*h[uxC`|oFbZRr՞gw[S[oWO,O=ONӠ!O.]5*= !ˆGWsHCIm6sήVpatzSjuМpH|es#d}[X4q477/ҭuփñCTb%O<_S`F=`4#5F{p+zWؽҔCV3ٜ(O/ꖮ KrKyINh{>gwG>\zOR݃DVzB?eGc}4GVvIQv@*TRE)]W @zYVϮ$/+昵_{RUEW+@պhRm}Vyc`;~42R3{MdHnLW͞$8ZM$0$V|Jy#.իx'Ibl}E_bR֥?!(IJJF k:rY:}X>kp\X*qWwа=MtNyzL^|e%C>~M/-_^5_Jd:8BR +T~6B׏X Lj.K,4H+^9r028ˬZQ ꅕ&ۅ!A{}1E:sbj)!%M҈=$~b˝E{_#y\J czTi!|ei#UMLcH֒[-:XJI}HFۡ*צXKqv!V^5̫ #cJT;YY$"WhC2Q{GQjq2"?,dR0m':>]g RJ:)Js+μ5PJV\+m:~ =<}Ws[tw ύ!PDy~4"*[tqΐ\[TM#$`iw .*c 9I=ƅF*TKKDU@HWepSj֮YM.EkRܘ! TXue9e Dfܵ.\r%"m{ACN2OTfu{kTtѽ "}5e8ۀB}wRq6i;\o1I1 0vzWfJYeiXy+j 5m%M@I)<{@^8]rRXRjR;SÌ$XI HOWUZ?QJkXo V~^ݐTی˪ߪ"#V2bf)\-*YDl͖؋isqysM\ Ÿs[NJ ՗V>< a#Uu&,X4ߩsZ]#['\R]g0ޏё:$X"-j?Pm D2:K7Gҗ^߼C2үw5g J(tZRyy8VtE ~< {TSOUcQK}\JR4(ʕ(sX_ )-مoa@V[SsjE)URQ7`]WBX -\J/Ks])?ި&:*PrlrS*Tx1iv2syUvR)3vrRJ2-